Covered, compounding — a small yield. A 0.59% yield on a $0.255 quarterly dividend, declared in September 2026, is covered many times over by cash: fiscal Q3 2026 free cash flow was $439 million against $72 million of dividends paid, and net leverage was about 1×. The yield is thin for an income card, but it is earned, and the dividend keeps rising — from $0.248 a quarter a year earlier.
Key risk: Life-science spending cycles — pharma, academia and government budgets drive instrument orders, and a funding pullback or tariff pressure lands on revenue before it lands on the dividend.
Changes if: Free cash flow stops covering the quarterly dividend several times over, or the raise streak breaks. Cash coverage, not the headline yield, is the tripwire here.
- ✓Payout-coverage check: Fiscal Q3 2026 free cash flow of $439 million covered $72 million of dividends paid more than six times over, with net leverage of about 1×.
- !Yield check: 0.59% indicated — $0.255/qtr × 4 at the $173.07 close on Oct. 23, 2026. Real, earned yield, but thin for an income-first card.
- ✓Dividend growth check: Raised to $0.255 a quarter in September 2026 from $0.248 a year earlier; fiscal 2025 dividends declared were $0.992 per share, up from $0.944 in fiscal 2024.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.